BCR-ABL1 E255K
|
CML
|
BCR-ABL1 E255K
|
CML
|
nilotinib Resistant: A2 - Guideline
|
nilotinib Resistant: A2 - Guideline
|
BCR-ABL1 E255K
|
ALL
|
BCR-ABL1 E255K
|
ALL
|
nilotinib Resistant: A2 - Guideline
|
nilotinib Resistant: A2 - Guideline
|
BCR-ABL1 E255K
|
CML
|
BCR-ABL1 E255K
|
CML
|
dasatinib Sensitive: B - Late Trials
|
dasatinib Sensitive: B - Late Trials
|
BCR-ABL1 E255K
|
ALL
|
BCR-ABL1 E255K
|
ALL
|
dasatinib + blinatumomab Sensitive: C3 – Early Trials
|
dasatinib + blinatumomab Sensitive: C3 – Early Trials
|
BCR-ABL1 E255K
|
CML
|
BCR-ABL1 E255K
|
CML
|
bosutinib Resistant: C3 – Early Trials
|
bosutinib Resistant: C3 – Early Trials
|
BCR-ABL1 E255K
|
CML
|
BCR-ABL1 E255K
|
CML
|
imatinib Resistant: C3 – Early Trials
|
imatinib Resistant: C3 – Early Trials
|
BCR-ABL1 E255K
|
ALL
|
BCR-ABL1 E255K
|
ALL
|
ponatinib Resistant: C3 – Early Trials
|
ponatinib Resistant: C3 – Early Trials
|
BCR-ABL1 E255K
|
B Acute Lymphoblastic Leukemia
|
BCR-ABL1 E255K
|
B Acute Lymphoblastic Leukemia
|
S81694 Sensitive: D – Preclinical
|
S81694 Sensitive: D – Preclinical
|
BCR-ABL1 E255K
|
CML
|
BCR-ABL1 E255K
|
CML
|
CUDC-907 Sensitive: D – Preclinical
|
CUDC-907 Sensitive: D – Preclinical
|
BCR-ABL1 E255K
|
CML
|
BCR-ABL1 E255K
|
CML
|
dasatinib + imatinib Resistant: D – Preclinical
|
dasatinib + imatinib Resistant: D – Preclinical
|